化合物ER 50891 T22767

Product Introduction
Bioactivity


英文名: ER 50891

描述: ER-50891是一种强效的视黄酸受体α（RARα）拮抗剂。ER-50891能减少全价视黄酸的抑制作用并恢复骨形态生成蛋白2诱导的成骨细胞分化。

体外活性: ER-50891 significantly antagonized the inhibition of ATRA and enhanced the total cell metabolic activity and proliferation of preosteoblasts. Dose-dependent assays show ER-50891 could also rescue ATRA inhibited OCN expression and mineralization with or without the induction of BMP. ER-50891 also suppressed the ALP activity that was synergistically enhanced by BMP and ATRA. Neither ATRA, nor ER-50891 or their combination significantly affected the level of BMP-induced phosphorylated Smad1/5. The antagonist of RARα, ER-50891 could significantly attenuate ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis.[3]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 38.7 mg/mL (90.0 mM)


关键字: ER50891 | ER 50891 | ER-50891

相关产品: Liarozole | trifarotene | Tazarotene | Oxybenzone | LY2955303 | AC-261066 | UVI 3003 | LG-100064 | HX 531 | WYC-209

相关库: Bioactive Compounds Library Max | Nuclear Receptor Compound Library | Bioactive Compound Library

化合物ER 50891 T22767信息由TargetMol中国为您提供，如您想了解更多关于化合物ER 50891 T22767报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途